("e-therapeutics" or the "Company")
Oxford, UK, 26 October 2021 - e-therapeutics plc (AIM: ETX; OTCQX: ETXPF), a specialist in computational drug discovery with a focus on developing RNA interference ("RNAi") therapeutics, announces the following dealing in the Company's ordinary shares of 0.1 pence each ("Ordinary Shares").
Earlier today, Mr Ali Mortazavi, the Company's Chief Executive Officer, purchased 275,000 Ordinary Shares at a price of 36.5 pence each.
Following the transaction, Mr Mortazavi is benefically interested in 50,941,666 Ordinary Shares, representing 9.9% of the Company's total issued share capital.
The notification below, made in accordance with the requirements of the EU Market Abuse Regulation, provides further details:
Details of the person discharging managerial responsibilities/person closely associated
Reason for the notification
Chief Executive Officer
Initial notification/ Amendment
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
Description of the financial instrument, type of instrument
Ordinary Shares of 0.1 pence
Nature of the transaction
Purchase of shares
Price(s) and volume(s)
275,000 ordinary shares at a price of 36.5 pence per share
- Aggregated volume
275,000 ordinary shares
36.5 pence per share
Aggregated value: £100,375
Date of the transaction
26 October 2021
Place of the transaction
Tel: +44 (0)1993 883 125
Ali Mortazavi, CEO
Karl Keegan, CFO
SP Angel Corporate Finance LLP
Tel: +44(0)20 3470 0470
Nominated Adviser and Broker
Matthew Johnson/Caroline Rowe (Corporate Finance)
Vadim Alexandre/Rob Rees (Corporate Broking)
About e-therapeutics plc
e-therapeutics plc is an Oxford, UK-based company integrating computational power and biology to accelerate the discovery of life-transforming medicines. The Company has developed and validated a powerful, disease and modality agnostic computational approach to drug discovery, leveraging its industry-leading expertise in network biology to fully capture and interrogate human disease complexity.
The Company's multi-disciplinary team builds computational models of biological functions to transform the search for new medicines, interventions, mechanisms and genetic support. Its biology-led in silico laboratory enables rapid hypothesis generation and phenotypic screening of millions of compounds leading to 100-1000x higher hit rates in the wet lab and successful mode of action elucidation. Novel targets can also be identified, prioritised and assessed. Harnessing internal target gene discoveries, e-therapeutics is currently building an in-house pipeline of RNAi based medicines, using its proprietary GalNAc-siRNA technology.
e-therapeutics has deployed and validated its disease-agnostic computational drug discovery platform both in house and with partners, including Novo Nordisk, Galapagos NV and a US-based, top 5 pharmaceutical company.